Initial public offering (IPO) listing outcomes are of substantial interest to retail investors, underwriters, and regulators, yet remain notoriously difficult to predict from pre-listing fundamentals alone. This study develops and evaluates a complete predictive modelling workflow for the Indian IPO market, combining regression analysis and deep learning to estimate four core outputs: an interpretable IPO Risk Score (0–100), an IPO Investment Score (0–100), the probability of a successful (positive) listing-day return, and the expected listing-day gain percentage. From an assembled dataset of 880 Indian mainboard IPOs (2006–2026) compiled from Chittorgarh, SEBI, the National Stock Exchange (NSE), and yfinance, 825 verified, leakage-free offerings were finalized after systematically resolving target listing returns and sanitizing 48 active fundamental, valuation, and macroeconomic features. In classification, a calibrated HistGradientBoosting model (ROC-AUC: 0.617, Log Loss: 0.635, Balanced Accuracy: 57.73% at optimal threshold 0.670) and a 10-fold bagged regularized deep multilayer perceptron (ROC-AUC: 0.618, Log Loss: 0.756, Balanced Accuracy: 57.73%) were compared and ensembled. Blending both paradigms yielded the strongest overall discrimination (ROC-AUC: 0.626, Log Loss: 0.645, Balanced Accuracy: 58.18%) with a 70.9% inter-model prediction agreement. For listing-day gain regression, HistGradientBoosting with absolute-error loss achieved MAE = 25.49% and RMSE = 38.50% (R² = 0.0381), consistently outperforming the naive mean baseline (MAE: 27.58%, RMSE: 39.29%), whereas deep learning neural regressors (including a 3-year sequential LSTM) encountered an information ceiling on tabular returns. Model explainability via SHAP highlights short-term index momentum, trailing revenue, balance-sheet scale, and composite scorecards as primary drivers. Finally, the complete dual-engine architecture was operationalized into an interactive web application featuring real-time prospectus scraping for ongoing IPOs and live index tracking, providing an actionable, uncertainty-aware decision-support tool for retail investors.
No takes yet. Share an insight, caveat, or question.
LABDHI BAUA (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: